Goldman Sachs' analysis ranks Johnson & Johnson (NYSE:JNJ) 6th among popular stocks with mutual fund managers. Despite legal challenges impacting its share price, JNJ is investing in new treatments and expanding biologic production. For potential higher returns, consider AI stocks.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing